CO2024000572A2 - Compuestos pirimidínicos para usar como inhibidores de map4k1 - Google Patents

Compuestos pirimidínicos para usar como inhibidores de map4k1

Info

Publication number
CO2024000572A2
CO2024000572A2 CONC2024/0000572A CO2024000572A CO2024000572A2 CO 2024000572 A2 CO2024000572 A2 CO 2024000572A2 CO 2024000572 A CO2024000572 A CO 2024000572A CO 2024000572 A2 CO2024000572 A2 CO 2024000572A2
Authority
CO
Colombia
Prior art keywords
map4k1
compounds
pyrimidine compounds
inhibitors
map4k1 inhibitors
Prior art date
Application number
CONC2024/0000572A
Other languages
English (en)
Spanish (es)
Inventor
Pravin Iyer
Sanjib Das
Murugan Chinnapattu
Sachin Chaudhari
Jagmohan Saini
Sravan Mandadi
Nagaraj Gowda
Dnyaneshwar Dahale
Sandip Patil
Nanasaheb Kadlag
Chandrasekhar Misra
Priyanka Pangare
Original Assignee
Glenmark Specialty Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Specialty Sa filed Critical Glenmark Specialty Sa
Publication of CO2024000572A2 publication Critical patent/CO2024000572A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2024/0000572A 2021-07-06 2024-01-24 Compuestos pirimidínicos para usar como inhibidores de map4k1 CO2024000572A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121030204 2021-07-06
PCT/IB2022/056248 WO2023281417A1 (en) 2021-07-06 2022-07-06 Pyrimidine compounds for use as map4k1 inhibitors

Publications (1)

Publication Number Publication Date
CO2024000572A2 true CO2024000572A2 (es) 2024-02-05

Family

ID=82703212

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0000572A CO2024000572A2 (es) 2021-07-06 2024-01-24 Compuestos pirimidínicos para usar como inhibidores de map4k1

Country Status (14)

Country Link
US (1) US12577267B2 (https=)
EP (1) EP4367123A1 (https=)
JP (1) JP2024527565A (https=)
KR (1) KR20240012538A (https=)
CN (1) CN117730083A (https=)
AU (1) AU2022305807B2 (https=)
CA (1) CA3223874A1 (https=)
CL (1) CL2023003791A1 (https=)
CO (1) CO2024000572A2 (https=)
EC (1) ECSP24007193A (https=)
IL (1) IL309342A (https=)
MX (1) MX2023015246A (https=)
PE (1) PE20240585A1 (https=)
WO (1) WO2023281417A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231875A1 (en) 2023-05-09 2024-11-14 Glenmark Specialty S.A. Hpk1 inhibitor for use in the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2792979T3 (es) * 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
WO2018102366A1 (en) * 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
AU2020406824A1 (en) * 2019-12-16 2022-08-11 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative and use thereof

Also Published As

Publication number Publication date
AU2022305807A1 (en) 2024-01-04
AU2022305807B2 (en) 2024-09-05
JP2024527565A (ja) 2024-07-25
US20230227483A1 (en) 2023-07-20
MX2023015246A (es) 2024-01-19
CN117730083A (zh) 2024-03-19
US12577267B2 (en) 2026-03-17
WO2023281417A1 (en) 2023-01-12
CA3223874A1 (en) 2023-01-12
PE20240585A1 (es) 2024-03-21
CL2023003791A1 (es) 2024-07-12
IL309342A (en) 2024-02-01
KR20240012538A (ko) 2024-01-29
ECSP24007193A (es) 2024-03-01
EP4367123A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
CL2022002579A1 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
PY2019955A (es) Inhibidores de inflamasoma nlrp3
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CR11491A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2025010799A (es) Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a)
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
CR20210661A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
UY30862A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacioon y aplicaciones
UY31812A (es) Derivados de cinolina como inhibidores de csf-1
AR069569A1 (es) Derivados de benzoxazina, un intermediario para su preparacion, una composicion farmaceutica que los comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de renina.
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.
AR131509A1 (es) Inhibidores del inflamasoma nlrp3
CU20140021A7 (es) Derivados de 2- amino-4- (piridin-2-il)-5,6- dihidro-4h-1,3- oxacina y su uso como inhibidores de bace -1 y/o bace-2